SuperworthBriaCell Therapeutics price to book ratio BCTX
Market value divided by the book value of the company's net assets, since 2022.
- Today, Oct 23, 2026
- 1.2×
- 4-year median
- 1.6×
- Against its 4-year history
- 35th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.4× to 34.4×
- Peer median
- 1.5×
BriaCell Therapeutics' price to book ratio is 1.2× as of Oct 23, 2026.
That is below its 4-year median of 1.6×, lower than on 65% of days in the last 4 years.
Over that time it ranged from 0.4× in Aug 2025 to 34.4× in Dec 2023.
The median for 4 large drugmakers of a similar size is 1.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.2× | 0.7× | 1.6× |
| 2025 | 1.5× | 0.4× | 7.0× |
| 2024 | 6.1× | 6.1× | 31.7× |
| 2023 | 34.4× | 8.1× | 34.4× |
| 2022 | 6.6× | 6.6× | 8.7× |
Against its peers
Companies in Drug Manufacturers - General nearest BriaCell Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| BCTXBriaCell Therapeutics | 1.2× |
| ATNMActinium Pharmaceuticals | 1.6× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| NATRNatures Sunshine Products | 1.3× |
| Peer median | 1.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on BriaCell Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.